Página 1 a partir de 82 resultados
BACKGROUND
The dipeptidyl peptidase-4 (DPP-4) inhibitors Sitagliptin and Vildagliptin lower blood glucose by augmenting endogenous levels of glucagon-like peptide-1 (GLP-1), an incretin which also confers cardioprotection. As such, we hypothesized that treatment with DPP-4 inhibitors are also
The development of myocardial infarction was shown to be accompanied by a rise in blood cAMP, cGMP and AMP levels, cyclic nucleotides peaking within the first hours of the disease. The increase in plasma cAMP, associated with developing heart failure, was more persistent. The administration of GIP
In order to limit the spread of myocardial infarction, 56 patients with acute myocardial infarction, admitted to hospital within 10 hours from the attack, were for two days treated with continuous intravenous drip infusion of glucose-insulin-potassium mixture (GIP) (300 ml glucose, 50 U common
In order to limit the spread of myocardial infarction, 56 patients with acute myocardial infarction, admitted to hospital within 10 hours after the attack, for two days received continuous intravenous drip infusion of glucose-insulin-potassium mixture (GIP) containing: 300 ml glucose, 50 U common
From 1972 to 1975, we have observed seven patients with localized pulmonary consolidation distal to the tip of a Swan-Ganz catheter. These seven instances occurred in a population of over 300 patients receiving a hypertonic solution of glucose, insulin, and potassium for acute myocardial infarction.
OBJECTIVE
Clinical and experimental investigations demonstrated that metformin, a widely used anti-diabetic drug, exhibits cardioprotective properties against myocardial infarction. Interestingly, metformin was previously shown to increase the expression of PGC-1α a key controller of energy
The relationship between the antilipolytic action of glucose and the parameters characterizing the weight and state of the adipose tissue was studied in 60 patients with acute myocardial infarction. The amount of fat in the body was assessed, and the morphological structure of the adipose tissue
Fifty-four patients with AMI were treated with a front-loaded 15-hour infusion of hypertonic glucose, insulin, potassium, magnesium, and L-carnitine in addition to usual therapy. This metabolic solution was well tolerated, free of serious side effects, and reduced the incidence of morbid events.
A 57-year-old right-handed man presented with speech disturbance 1 day prior to his admission. The standardized aphasia test batteries showed transcortical sensory aphasia. MRI revealed a left frontal and insular infarct. Positron emission tomography scans also revealed a glucose hypometabolism in
Blood glucose control in patients with diabetes after myocardial infarction is often poor, and this may contribute to increased mortality in the diabetic patient. A retrospective review of the records of 71 diabetic patients admitted with suspected myocardial infarction, and managed using a variety
341 patients with acute myocardial infarction have been treated in intensive or coronary care units. They were randomised into two groups, 172 receiving urokinase and 169 receiving a glucose infusion. Thereafter they were anticoagulated first with heparin and then for a year with oral
Among the last consequences of metabolic syndrome are cardiovascular complications such as infarcts. The hypoxic heart switches its lipid-based metabolism to carbohydrates, and a glucose-insulin-potassium (GIK) solution can be the metabolic support to protect the organ. Due to the physiology and
A prospective experiment was carried out in 56 patients undergoing coronary artery revascularization to determine whether those having a glucose-insulin-potassium (GIK) perfusion during the procedure would have fewer myocardial infarctions (MI) compared with patients given a control perfusion of
OBJECTIVE
to investigate the association between admission hyperglycemia and myocardial damage in patients with ST-segment elevation myocardial infarction (STEMI) using Cardiac Magnetic Resonance (CMR).
METHODS
We analyzed 113 patients with STEMI treated with successful primary percutaneous coronary